Berry, S. H. et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J. Urol. 186, 540–544. doi.org/10.1016/j.juro.2011.03.132 (2011).
Akiyama, Y., Homma, Y. & Maeda, D. Pathology and terminology of interstitial cystitis/bladder pain syndrome: A review. Histol. Histopathol. 34, 25–32. doi.org/10.14670/hh-18-028 (2019).
Sant, G. R. & Theoharides, T. C. Interstitial cystitis. Curr. Opin. Urol. 9, 297–302. doi.org/10.1097/00042307-199907000-00004 (1999).
Homma, Y. et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int. J. Urol. 27, 578–589. doi.org/10.1111/iju.14234 (2020).
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395, 565–574. doi.org/10.1016/s0140-6736(20)30251-8 (2020).
Chilamakuri, R. & Agarwal, S. COVID-19: Characteristics and therapeutics. Cells doi.org/10.3390/cells10020206 (2021).
Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506. doi.org/10.1016/s0140-6736(20)30183-5 (2020).
Xu, D. et al. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. Eur. J. Clin. Microbiol. Infect. Dis. 24, 165–171. doi.org/10.1007/s10096-005-1299-5 (2005).
Tiryaki, S., Egil, O., Birbilen, A. Z. & Buyukcam, A. COVID-19 associated lower urinary tract symptoms in children. J. Pediatr. Urol. 18(680), e681-680.e687. doi.org/10.1016/j.jpurol.2022.08.018 (2022).
Dhar, N. et al. De novo urinary symptoms associated with COVID-19: COVID-19-associated cystitis. J. Clin. Med. Res. 12, 681–682. doi.org/10.14740/jocmr4294 (2020).
Lamb, L. E. et al. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Med. Hypotheses 145, 110375. doi.org/10.1016/j.mehy.2020.110375 (2020).
Li, M. Y., Li, L., Zhang, Y. & Wang, X. S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect. Dis. Pov. 9, 45. doi.org/10.1186/s40249-020-00662-x (2020).
Ehrenfeld, M. et al. Covid-19 and autoimmunity. Autoimmun. Rev. 19, 102597. doi.org/10.1016/j.autrev.2020.102597 (2020).
Szekanecz, Z. et al. COVID-19: Autoimmunity, multisystemic inflammation and autoimmune rheumatic patients. Expert Rev. Mol. Med. 24, e13. doi.org/10.1017/erm.2022.10 (2022).
Cavalcante-Silva, L. H. A. et al. Neutrophils and COVID-19: The road so far. Int. Immunopharmacol. 90, 107233. doi.org/10.1016/j.intimp.2020.107233 (2021).
Castanheira, F. V. S. & Kubes, P. Neutrophils and NETs in modulating acute and chronic inflammation. Blood 133, 2178–2185. doi.org/10.1182/blood-2018-11-844530 (2019).
Edgar, R., Domrachev, M. & Lash, A. E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207–210. doi.org/10.1093/nar/30.1.207 (2002).
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47. doi.org/10.1093/nar/gkv007 (2015).
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: An R package for comparing biological themes among gene clusters. Omics 16, 284–287. doi.org/10.1089/omi.2011.0118 (2012).
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. doi.org/10.1093/nar/28.1.27 (2000).
Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951. doi.org/10.1002/pro.3715 (2019).
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587-d592. doi.org/10.1093/nar/gkac963 (2023).
Gene Ontology Consortium. Going forward. Nucleic Acids Res. 43, D1049-1056. doi.org/10.1093/nar/gku1179 (2015).
Szklarczyk, D. et al. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638-d646. doi.org/10.1093/nar/gkac1000 (2023).
Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504. doi.org/10.1101/gr.1239303 (2003).
Chin, C. H. et al. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8(Suppl 4), S11. doi.org/10.1186/1752-0509-8-s4-s11 (2014).
Xia, J., Gill, E. E. & Hancock, R. E. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat. Protoc. 10, 823–844. doi.org/10.1038/nprot.2015.052 (2015).
Castro-Mondragon, J. A. et al. JASPAR 2022: The 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 50, D165-d173. doi.org/10.1093/nar/gkab1113 (2022).
Chou, C. H. et al. miRTarBase update 2018: A resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 46, D296-d302. doi.org/10.1093/nar/gkx1067 (2018).
Karagkouni, D. et al. DIANA-TarBase v8: A decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res. 46, D239-d245. doi.org/10.1093/nar/gkx1141 (2018).
Piñero, J. et al. DisGeNET: A comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 45, D833-d839. doi.org/10.1093/nar/gkw943 (2017).
Yoo, M. et al. DSigDB: Drug signatures database for gene set analysis. Bioinformatics 31, 3069–3071. doi.org/10.1093/bioinformatics/btv313 (2015).
Kuleshov, M. V. et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90-97. doi.org/10.1093/nar/gkw377 (2016).
Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18, 248–262. doi.org/10.1016/j.celrep.2016.12.019 (2017).
Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7. doi.org/10.1186/1471-2105-14-7 (2013).
Robin, X. et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12, 77. doi.org/10.1186/1471-2105-12-77 (2011).
Lu, L. et al. Discovering common pathogenetic processes between COVID-19 and sepsis by bioinformatics and system biology approach. Front. Immunol. 13, 975848. doi.org/10.3389/fimmu.2022.975848 (2022).
Zhang, Y. et al. Identification of 3 key genes as novel diagnostic and therapeutic targets for OA and COVID-19. Front. Immunol. 14, 1167639. doi.org/10.3389/fimmu.2023.1167639 (2023).
Umakanthan, S. et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad. Med. J. 96, 753–758. doi.org/10.1136/postgradmedj-2020-138234 (2020).
Dhawan, A. et al. COVID-associated cystitis: The culprit behind the bladder woes post-COVID infection? A review. Int. Urol. Nephrol. doi.org/10.1007/s11255-023-03700-3 (2023).
Wang, Y. & Perlman, S. COVID-19: Inflammatory profile. Annu. Rev. Med. 73, 65–80. doi.org/10.1146/annurev-med-042220-012417 (2022).
Merad, M., Blish, C. A., Sallusto, F. & Iwasaki, A. The immunology and immunopathology of COVID-19. Science 375, 1122–1127. doi.org/10.1126/science.abm8108 (2022).
Peng, L. et al. Integrating single-cell RNA sequencing with spatial transcriptomics reveals immune landscape for interstitial cystitis. Signal Transd. Target. Ther. 7, 161. doi.org/10.1038/s41392-022-00962-8 (2022).
Ashraf, U. M. et al. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol. Genom. 53, 51–60. doi.org/10.1152/physiolgenomics.00087.2020 (2021).
Muralidar, S., Ambi, S. V., Sekaran, S. & Krishnan, U. M. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie 179, 85–100. doi.org/10.1016/j.biochi.2020.09.018 (2020).
Kempuraj, D. et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist 26, 402–414. doi.org/10.1177/1073858420941476 (2020).
Azkur, A. K. et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 75, 1564–1581. doi.org/10.1111/all.14364 (2020).
Yu, W. R., Jiang, Y. H., Jhang, J. F. & Kuo, H. C. Use of urinary cytokine and chemokine levels for identifying bladder conditions and predicting treatment outcomes in patients with interstitial cystitis/bladder pain syndrome. Biomedicines doi.org/10.3390/biomedicines10051149 (2022).
Malik, S. T. et al. Distribution of mast cell subtypes in interstitial cystitis: Implications for novel diagnostic and therapeutic strategies?. J. Clin. Pathol. 71, 840–844. doi.org/10.1136/jclinpath-2017-204881 (2018).
Li, D. P. et al. LILRB2/PirB mediates macrophage recruitment in fibrogenesis of nonalcoholic steatohepatitis. Nat. Commun. 14, 4436. doi.org/10.1038/s41467-023-40183-3 (2023).
Fotouhi-Ardakani, N. et al. Role for myeloid nuclear differentiation antigen in the regulation of neutrophil apoptosis during sepsis. Am. J. Respir. Crit. Care Med. 182, 341–350. doi.org/10.1164/rccm.201001-0075OC (2010).
Ungerbäck, J. et al. Pioneering, chromatin remodeling, and epigenetic constraint in early T-cell gene regulation by SPI1 (PU.1). Genome Res. 28, 1508–1519. doi.org/10.1101/gr.231423.117 (2018).
Zhang, Y. F., Meng, L. B., Hao, M. L., Li, X. Y. & Zou, T. CXCR4 and TYROBP mediate the development of atrial fibrillation via inflammation. J. Cell. Mol. Med. 26, 3557–3567. doi.org/10.1111/jcmm.17405 (2022).
Yu, Y. L. et al. STAT1 epigenetically regulates LCP2 and TNFAIP2 by recruiting EP300 to contribute to the pathogenesis of inflammatory bowel disease. Clin. Epigenet. 13, 127. doi.org/10.1186/s13148-021-01101-w (2021).
Liu, H. et al. The immune adaptor SLP-76 binds to SUMO-RANGAP1 at nuclear pore complex filaments to regulate nuclear import of transcription factors in T cells. Mol. Cell 59, 840–849. doi.org/10.1016/j.molcel.2015.07.015 (2015).
Küster, H., Thompson, H. & Kinet, J. P. Characterization and expression of the gene for the human Fc receptor gamma subunit: Definition of a new gene family. J. Biol. Chem. 265, 6448–6452 (1990).
Fu, L. et al. Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma. J. Cancer 11, 1182–1194. doi.org/10.7150/jca.37313 (2020).
Amo, G. et al. FCERI and histamine metabolism gene variability in selective responders to NSAIDS. Front. Pharmacol. 7, 353. doi.org/10.3389/fphar.2016.00353 (2016).
Zhou, M. et al. Deficiency of ITGAM attenuates experimental abdominal aortic aneurysm in mice. J. Am. Heart Assoc. 10, e019900. doi.org/10.1161/jaha.120.019900 (2021).
Siekacz, K. et al. Soluble ITGaM and ITGb2 integrin subunits are involved in long-term pulmonary complications after COVID-19 infection. J. Clin. Med. doi.org/10.3390/jcm12010342 (2023).
Pilione, M. R., Agosto, L. M., Kennett, M. J. & Harvill, E. T. CD11b is required for the resolution of inflammation induced by Bordetella bronchiseptica respiratory infection. Cell. Microbiol. 8, 758–768. doi.org/10.1111/j.1462-5822.2005.00663.x (2006).
Cui, X. et al. Cystitis-induced bladder pain is Toll-like receptor 4 dependent in a transgenic autoimmune cystitis murine model: A MAPP Research Network animal study. Am. J. Physiol. Renal Physiol. 317, F90-f98. doi.org/10.1152/ajprenal.00017.2019 (2019).
Ahmed, F. F. et al. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches. PLoS ONE 17, e0266124. doi.org/10.1371/journal.pone.0266124 (2022).
Islam, T. et al. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19. Eur. J. Pharmacol. 887, 173594. doi.org/10.1016/j.ejphar.2020.173594 (2020).
Mahal, A., Young-Lin, N., Dobberfuhl, A., Estes, J. & Comiter, C. V. Peroxisome proliferator-activated receptor gamma agonist as a novel treatment for interstitial cystitis: A rat model. Investig. Clin. Urol. 59, 257–262. doi.org/10.4111/icu.2018.59.4.257 (2018).
Ciavarella, C., Motta, I., Valente, S. & Pasquinelli, G. Pharmacological (or synthetic) and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in COVID-19 disease. Molecules doi.org/10.3390/molecules25092076 (2020).
Paniri, A., Hosseini, M. M., Moballegh-Eslam, M. & Akhavan-Niaki, H. Comprehensive in silico identification of impacts of ACE2 SNPs on COVID-19 susceptibility in different populations. Gene Rep. 22, 100979. doi.org/10.1016/j.genrep.2020.100979 (2021).
Wicik, Z. et al. ACE2 interaction networks in COVID-19: A physiological framework for prediction of outcome in patients with cardiovascular risk factors. J. Clin. Med. doi.org/10.3390/jcm9113743 (2020).
Zhong, G. et al. miRNA-335-5p relieves chondrocyte inflammation by activating autophagy in osteoarthritis. Life Sci. 226, 164–172. doi.org/10.1016/j.lfs.2019.03.071 (2019).
Song, Y. et al. Dysregulation of pseudogenes/lncRNA-Hsa-miR-1-3p-PAICS pathway promotes the development of NSCLC. J. Oncol. 2022, 4714931. doi.org/10.1155/2022/4714931 (2022).
Chen, P. et al. MicroRNA-192 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting caveolin 1. Oncol. Rep. 42, 1667–1676. doi.org/10.3892/or.2019.7298 (2019).
Fierro-Fernández, M. et al. miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2. EMBO Rep. 16, 1358–1377. doi.org/10.15252/embr.201540750 (2015).
George, P. M., Wells, A. U. & Jenkins, R. G. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir. Med. 8, 807–815. doi.org/10.1016/s2213-2600(20)30225-3 (2020).
Cabibbo, G., Rizzo, G. E. M., Stornello, C. & Craxì, A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J. Viral Hepat. 28, 4–11. doi.org/10.1111/jvh.13440 (2021).
Baldelli, L. et al. SARS-CoV-2 infection and liver disease: A review of pathogenesis and outcomes. Gut Liver 17, 12–23. doi.org/10.5009/gnl220327 (2023).
Marjot, T. et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J. Hepatol. 74, 567–577. doi.org/10.1016/j.jhep.2020.09.024 (2021).
DeLisi, L. E. A commentary revisiting the viral hypothesis of schizophrenia: Onset of a schizophreniform disorder subsequent to SARS CoV-2 infection. Psychiatry Res. 295, 113573. doi.org/10.1016/j.psychres.2020.113573 (2021).
Kowalski, K. & Misiak, B. Schizophrenia and the COVID-19 pandemic: A narrative review from the biomedical perspective. Rev. Psiquiatr Salud. Ment. doi.org/10.1016/j.rpsm.2023.04.002 (2023).
Cao, Z. et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of covid-19. N. Engl. J. Med. 388, 406–417. doi.org/10.1056/NEJMoa2208822 (2023).
Dey, D., Borkotoky, S. & Banerjee, M. In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor. Comput. Biol. Med. 127, 104063. doi.org/10.1016/j.compbiomed.2020.104063 (2020).
Ahmed, M., Farag, A., Boys, I. N. & Sadek, H. Identification of Atovaquone and Mebendazole as Repurposed Drugs with Antiviral Activity against SARS-CoV-2 (Version 6). (2021).
Galal, M. W. et al. The use of mebendazole in COVID-19 patients: An observational retrospective single center study. Adv. Virol. 2022, 3014686. doi.org/10.1155/2022/3014686 (2022).
Banerjee, N. S., Moore, D. W., Broker, T. R. & Chow, L. T. Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc. Natl. Acad. Sci. USA 115, E11138-e11147. doi.org/10.1073/pnas.1801156115 (2018).
Sixto-López, Y. & Correa-Basurto, J. HDAC inhibition as neuroprotection in COVID-19 infection. Curr. Top. Med. Chem. 22, 1369–1378. doi.org/10.2174/1568026622666220303113445 (2022).
Haldar, S. et al. Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis. Sci. Rep. 6, 39257. doi.org/10.1038/srep39257 (2016).
Wik, J. A. & Skålhegg, B. S. T cell metabolism in infection. Front. Immunol. 13, 840610. doi.org/10.3389/fimmu.2022.840610 (2022).
Schmidt, M. E. & Varga, S. M. The CD8 T cell response to respiratory virus infections. Front. Immunol. 9, 678. doi.org/10.3389/fimmu.2018.00678 (2018).
Murphy, K. & Weaver, C. Janeway’s Immunobiology (Garland science, 2016).
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501. doi.org/10.1016/j.cell.2020.05.015 (2020).
Kneilling, M. et al. Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. Blood 114, 1696–1706. doi.org/10.1182/blood-2008-11-187682 (2009).
Metcalfe, D. D., Baram, D. & Mekori, Y. A. Mast cells. Physiol. Rev. 77, 1033–1079. doi.org/10.1152/physrev.1997.77.4.1033 (1997).
Ochoa, M. C. et al. Antibody-dependent cell cytotoxicity: Immunotherapy strategies enhancing effector NK cells. Immunol. Cell Biol. 95, 347–355. doi.org/10.1038/icb.2017.6 (2017).
Chua, R. L. et al. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol. 38, 970–979. doi.org/10.1038/s41587-020-0602-4 (2020).
Moldwin, R. M. et al. Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome. J. Transl. Med. 20, 97. doi.org/10.1186/s12967-022-03236-7 (2022).
